Skip to content

Author

Amarachi Obikaonu

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Nov 2026

Abstract 14909: GLP-1 Receptor Agonist Add-On Therapy versus Continued SGLT2 Inhibitor Monotherapy and Kidney Failure in Adults with Type 2 Diabetes and CKD Stages 3-4: A Propensity-Matched Real-World Analysis

Background: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) reduce kidney and cardiovascular risk in chronic kidney disease (CKD), yet residual risk remains substantial. Whether the addition of glucagon-like peptide-1 receptor agonists (GLP-1RA) provides incremental renal and cardiovascular benefit among patients...

Sylvia Osei-Akuamoah, Kwame Adjei-Sefah, Y. Kebede et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.